“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."
Largest contemporary randomized trial demonstrates benefit following myocardial infarction in patients with preserved or mildly reduced ejection fraction.
A morning BP rise of over 10 mmHg independently predicts left ventricular hypertrophy—accounting for 36.2% of LVMI variability, even after adjusting for age and BMI.
A study presented at RSNA 2024 demonstrated findings at midlife, decades prior to patients exhibiting early symptoms of Alzheimer's disease related dementia.